| scholarly article | Q13442814 |
| P356 | DOI | 10.1182/BLOOD-2007-06-093880 |
| P8608 | Fatcat ID | release_shmegekw3zdl5o7i5efmp5faai |
| P932 | PMC publication ID | 2234775 |
| P698 | PubMed publication ID | 17717135 |
| P50 | author | Marcel R.M. van den Brink | Q17198821 |
| Nancy A Kernan | Q46616560 | ||
| P2093 | author name string | Nancy Collins | |
| Miguel-Angel Perales | |||
| Ann A Jakubowski | |||
| Trudy N Small | |||
| Esperanza B Papadopoulos | |||
| Hugo Castro-Malaspina | |||
| Richard J O'Reilly | |||
| James W Young | |||
| Michelle Chiu | |||
| Katherine C Hsu | |||
| Christine Cisek | |||
| P2860 | cites work | Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461) | Q28209814 |
| Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials | Q30997153 | ||
| Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation | Q31828080 | ||
| Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. | Q34219078 | ||
| Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning | Q34404171 | ||
| Development of a real-time quantitative assay for detection of Epstein-Barr virus. | Q39455334 | ||
| Bone marrow transplantation across HLA barriers by increasing the number of transplanted cells. | Q40404351 | ||
| Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts. | Q41561745 | ||
| Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-v-host disease. | Q43605522 | ||
| Reduced-intensity conditioning allogeneic blood stem cell transplantation with fludarabine and oral busulfan with or without pharmacokinetically targeted busulfan dosing in patients with myeloid leukemia ineligible for conventional conditioning. | Q43696027 | ||
| CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling tr | Q43806486 | ||
| Graft failure after T-cell-depleted human leukocyte antigen identical marrow transplants for leukemia: I. Analysis of risk factors and results of secondary transplants | Q43882125 | ||
| Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor. | Q44471803 | ||
| Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning | Q44826910 | ||
| Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial | Q44980750 | ||
| Prevention of peritransplantation viridans streptococcal bacteremia with early vancomycin administration: a single-center observational cohort study. | Q45172493 | ||
| High doses of transplanted CD34+ cells are associated with rapid T-cell engraftment and lessened risk of graft rejection, but not more graft-versus-host disease after nonmyeloablative conditioning and unrelated hematopoietic cell transplantation | Q46384949 | ||
| High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma | Q46432999 | ||
| Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older | Q46433183 | ||
| A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in first or second complete remission | Q47603523 | ||
| Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. | Q54396385 | ||
| Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. | Q54684597 | ||
| Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the F | Q66829418 | ||
| T-cell-depleted allogeneic bone marrow transplantation in adults with acute nonlymphocytic leukemia in first remission | Q68140706 | ||
| Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors | Q70051817 | ||
| Hyperfractionated total body irradiation for bone marrow transplantation. results in seventy leukemia patients with allogeneic transplants | Q70301485 | ||
| Immune reconstitution following T-cell depleted bone marrow transplantation: effect of age and posttransplant graft rejection prophylaxis | Q73616488 | ||
| T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease | Q74106233 | ||
| Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia | Q74490480 | ||
| Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: effect of patient age and donor leukocyte infusions | Q77784647 | ||
| Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation | Q78102353 | ||
| Outcome of transplantation of highly purified peripheral blood CD34+ cells with T-cell add-back compared with unmanipulated bone marrow or peripheral blood stem cells from HLA-identical sibling donors in patients with first chronic phase chronic mye | Q78409850 | ||
| Prognostic factors of chronic graft-versus-host disease after allogeneic blood stem-cell transplantation | Q81585875 | ||
| Myeloablative allogeneic hematopoietic stem cell transplantation in elderly patients | Q82925213 | ||
| Extending postgrafting cyclosporine decreases the risk of severe graft-versus-host disease after nonmyeloablative hematopoietic cell transplantation | Q82996468 | ||
| Graft failure after T-cell-depleted human leukocyte antigen identical marrow transplants for leukemia: II. In vitro analyses of host effector mechanisms | Q93523550 | ||
| P433 | issue | 13 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 4552-4559 | |
| P577 | publication date | 2007-08-23 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | T cell depleted stem-cell transplantation for adults with hematologic malignancies: sustained engraftment of HLA-matched related donor grafts without the use of antithymocyte globulin | |
| P478 | volume | 110 |
| Q40121414 | A Chemotherapy-Only Regimen of Busulfan, Melphalan, and Fludarabine, and Rabbit Antithymocyte Globulin Followed by Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplantations for the Treatment of Myeloid Malignancies |
| Q41186091 | A prospective evaluation of changes in brain structure and cognitive functions in adult stem cell transplant recipients |
| Q48313602 | Activated MHC-mismatched T helper-1 lymphocyte infusion enhances GvL with limited GvHD. |
| Q34279672 | Adoptive transfer of unselected or leukemia-reactive T-cells in the treatment of relapse following allogeneic hematopoietic cell transplantation |
| Q50524323 | Adult Umbilical Cord Blood Transplantation Using Myeloablative Thiotepa, Total Body Irradiation, and Fludarabine Conditioning. |
| Q92148682 | Advances in Ex Vivo T Cell Depletion - Where Do We Stand? |
| Q37191057 | Advances in the treatment of acute graft-versus-host disease. |
| Q50079881 | Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndrome: Comparison of Outcomes between CD34+ Selected and Unmodified Hematopoietic Stem Cell Transplantation |
| Q34093150 | Allogeneic T cells impair engraftment and hematopoiesis after stem cell transplantation |
| Q36021536 | Arrhythmias in the setting of hematopoietic cell transplants |
| Q37395170 | Blood Stem Cell Activity Is Arrested by Th1-Mediated Injury Preventing Engraftment following Nonmyeloablative Conditioning. |
| Q50079874 | Blood and Marrow Transplant Clinical Trials Network Report on the Development of Novel Endpoints and Selection of Promising Approaches for Graft-versus-Host Disease Prevention Trials |
| Q50160436 | CD34+ Cell Selection versus Reduced-Intensity Conditioning and Unmodified Grafts for Allogeneic Hematopoietic Cell Transplantation in Patients Age >50 Years with Acute Myelogenous Leukemia and Myelodysplastic Syndrome . |
| Q36608689 | CD34-Selected Hematopoietic Stem Cell Transplants Conditioned with Myeloablative Regimens and Antithymocyte Globulin for Advanced Myelodysplastic Syndrome: Limited Graft-versus-Host Disease without Increased Relapse |
| Q33388255 | Chronic kidney disease, thrombotic microangiopathy, and hypertension following T cell-depleted hematopoietic stem cell transplantation |
| Q35889265 | Co-transplantation of pure blood stem cells with antigen-specific but not bulk T cells augments functional immunity |
| Q36212392 | Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell t |
| Q35243578 | Comparison of outcomes at two institutions of patients with ALL receiving ex vivo T-cell-depleted or unmodified allografts |
| Q88573546 | Defining success with cellular therapeutics: the current landscape for clinical end point and toxicity analysis |
| Q90586733 | Early Fluid Overload Is Associated with an Increased Risk of Nonrelapse Mortality after Ex Vivo CD34-Selected Allogeneic Hematopoietic Cell Transplantation |
| Q39028818 | Early recovery of T-cell function predicts improved survival after T-cell depleted allogeneic transplant |
| Q26799602 | Effects of T-Cell Depletion on Allogeneic Hematopoietic Stem Cell Transplantation Outcomes in AML Patients |
| Q35094029 | Engineering human peripheral blood stem cell grafts that are depleted of naïve T cells and retain functional pathogen-specific memory T cells |
| Q89748152 | Epstein-Barr virus reactivation after allogeneic hematopoietic stem cell transplantation: multifactorial impact on transplant outcomes |
| Q40407930 | Ex Vivo CD34+-Selected T Cell-Depleted Peripheral Blood Stem Cell Grafts for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Leukemia and Myelodysplastic Syndrome Is Associated with Low Incidence of Acute and Chronic Graft-versus-Host Di |
| Q33760933 | Ex vivo T cell-depleted versus unmodified allografts in patients with acute myeloid leukemia in first complete remission |
| Q57808500 | Ex vivo and in vivo T cell-depleted allogeneic stem cell transplantation in patients with acute myeloid leukemia in first complete remission resulted in similar overall survival: on behalf of the ALWP of the EBMT and the MSKCC |
| Q90911364 | Favorable long-term outcomes of hematopoietic stem cell transplantation for CMML with myeloablative conditioning, anti-thymocyte globulin, and CD34+ selected graft |
| Q40508324 | Hematopoietic Cell Transplantation Comorbidity Index Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Receiving CD34+ Selected Grafts for Allogeneic Hematopoietic Cell Transplantation. |
| Q36622322 | High Disease-Free Survival with Enhanced Protection against Relapse after Double-Unit Cord Blood Transplantation When Compared with T Cell-Depleted Unrelated Donor Transplantation in Patients with Acute Leukemia and Chronic Myelogenous Leukemia |
| Q37139105 | Histopathologic Features of Cutaneous Acute Graft-Versus-Host Disease in T-Cell-Depleted Peripheral Blood Stem Cell Transplant Recipients |
| Q41993908 | Impact of Toxicity on Survival for Older Adult Patients after CD34+ Selected Allogeneic Hematopoietic Stem Cell Transplantation. |
| Q34175284 | Impact of peri-transplant vancomycin and fluoroquinolone administration on rates of bacteremia in allogeneic hematopoietic stem cell transplant (HSCT) recipients: a 12-year single institution study |
| Q48680865 | In-vivo or ex-vivo T cell depletion or both to prevent graft-versus-host disease after hematopoietic stem cell transplantation. |
| Q37143051 | Late effects in patients with Fanconi anemia following allogeneic hematopoietic stem cell transplantation from alternative donors |
| Q33633514 | Long term renal survival in patients undergoing T-Cell depleted versus conventional hematopoietic stem cell transplants |
| Q49391428 | Long-term prognosis for 1-year relapse-free survivors of CD34+ cell-selected allogeneic hematopoietic stem cell transplantation: a landmark analysis |
| Q33745878 | Long-term survival in patients with peripheral T-cell non-Hodgkin lymphomas after allogeneic hematopoietic stem cell transplant |
| Q35148420 | Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: results of the blood and marrow transplant clinical trials networ |
| Q94538449 | Low toxicity and favorable overall survival in relapsed/refractory B-ALL following CAR T cells and CD34-selected T-cell depleted allogeneic hematopoietic cell transplant |
| Q35605318 | NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic ma |
| Q37504394 | Novel strategies for adoptive therapy following HLA disparate transplants |
| Q36040293 | Outcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts |
| Q33745865 | Palifermin is efficacious in recipients of TBI-based but not chemotherapy-based allogeneic hematopoietic stem cell transplants |
| Q52763577 | Partial T-cell depletion improves the composite endpoint graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic stem cell transplantation. |
| Q41604163 | Prospective assessment of white matter integrity in adult stem cell transplant recipients |
| Q36674480 | Quantitative assessment of T cell repertoire recovery after hematopoietic stem cell transplantation. |
| Q33917645 | Rapid reconstitution of antibody responses following transplantation of purified allogeneic hematopoietic stem cells |
| Q35167190 | Reduced late mortality risk contributes to similar survival after double-unit cord blood transplantation compared with related and unrelated donor hematopoietic stem cell transplantation |
| Q35623591 | Response to pneumococcal (PNCRM7) and haemophilus influenzae conjugate vaccines (HIB) in pediatric and adult recipients of an allogeneic hematopoietic cell transplantation (alloHCT) |
| Q37201899 | Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation |
| Q36863098 | Safety and immunogenicity of the live attenuated varicella vaccine following T replete or T cell-depleted related and unrelated allogeneic hematopoietic cell transplantation (alloHCT) |
| Q35778492 | Safety and immunogenicity of the tetravalent protein-conjugated meningococcal vaccine (MCV4) in recipients of related and unrelated allogeneic hematopoietic stem cell transplantation |
| Q42116164 | Second-line age-adjusted International Prognostic Index in patients with advanced non-Hodgkin lymphoma after T-cell depleted allogeneic hematopoietic SCT. |
| Q52580890 | Sequential systematic anti-mold prophylaxis with micafungin and voriconazole results in very low incidence of invasive mold infections in patients undergoing allogeneic hematopoietic stem cell transplantation. |
| Q37316816 | Stem cell transplantation in adults with acute myelogenous leukemia, normal cytogenetics, and the FLT3-ITD mutation |
| Q37000485 | Strategies to reduce relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia |
| Q37659142 | T cell-depleted stem cell transplantation for adults with high-risk acute lymphoblastic leukemia: long-term survival for patients in first complete remission with a decreased risk of graft-versus-host disease |
| Q34981585 | T cell-depleted unrelated donor stem cell transplantation provides favorable disease-free survival for adults with hematologic malignancies |
| Q38514497 | T-cell depleted allogeneic hematopoietic cell transplants as a platform for adoptive therapy with leukemia selective or virus-specific T-cells |
| Q37291642 | TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors |
| Q40058375 | The Effects of Late Toxicities on Outcomes in Long-Term Survivors of Ex-Vivo CD34+-Selected Allogeneic Hematopoietic Cell Transplantation. |
| Q35838113 | Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblings |
Search more.